CMPS vs. TVTX, SAGE, MGNX, NRIX, PRAX, RCKT, CPRX, ZLAB, GLPG, and NAMS
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Travere Therapeutics (TVTX), Sage Therapeutics (SAGE), MacroGenics (MGNX), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Zai Lab (ZLAB), Galapagos (GLPG), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Travere Therapeutics (NASDAQ:TVTX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
COMPASS Pathways has a net margin of 0.00% compared to COMPASS Pathways' net margin of -87.94%. Travere Therapeutics' return on equity of -57.24% beat COMPASS Pathways' return on equity.
46.2% of COMPASS Pathways shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Travere Therapeutics received 3 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 76.92% of users gave COMPASS Pathways an outperform vote while only 48.62% of users gave Travere Therapeutics an outperform vote.
Travere Therapeutics has higher revenue and earnings than COMPASS Pathways. Travere Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
In the previous week, Travere Therapeutics had 2 more articles in the media than COMPASS Pathways. MarketBeat recorded 3 mentions for Travere Therapeutics and 1 mentions for COMPASS Pathways. Travere Therapeutics' average media sentiment score of 1.87 beat COMPASS Pathways' score of 1.43 indicating that COMPASS Pathways is being referred to more favorably in the news media.
Travere Therapeutics presently has a consensus target price of $15.58, indicating a potential upside of 110.02%. COMPASS Pathways has a consensus target price of $47.40, indicating a potential upside of 542.28%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Travere Therapeutics.
Travere Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500.
Summary
COMPASS Pathways beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
